Every Form 4 that Veracyte, Inc. (VCYT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VCYT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCYT filings page.
VERACYTE, INC. (VCYT) reported that Jonathan Wygant, its VP and Chief Accounting Officer, had 1,361 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. This withholding is explicitly stated not to be a sale. After this transaction, he directly holds 43,226 shares, which include 514 shares purchased on July 31, 2026 under Veracyte’s Employee Stock Purchase Plan. No transactions are reported under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported an insider equity event involving Global Chief Commercial Officer John Leite. On September 2, 2026, Leite had 3,961 shares of common stock withheld at $44.88 per share to satisfy tax withholding obligations tied to vesting restricted stock units.
The filing states this was a tax-withholding disposition and not an open-market sale. After this transaction, Leite directly held 128,344 shares of Veracyte common stock. No transactions were made under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported that Chief Scientific & Med Officer Phillip G. Febbo sold common stock in planned transactions and had shares withheld for taxes. On September 4, 2026, he sold 10,405 shares at $42.8933 per share and 2,705 shares at $43.6618 per share in open-market or private transactions pursuant to a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,639 shares at $44.88 per share were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, which the company states does not represent a sale.
VERACYTE, INC. (VCYT) reported that Chief Financial Officer Rebecca Chambers sold common stock and had shares withheld for taxes. On September 4, 2026, she sold 2,477 shares at a weighted-average price of $42.8059 and 1,175 shares at $43.7140 in open-market or private transactions under a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,603 shares were withheld at $44.88 per share to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a sale.
VERACYTE, INC. (VCYT) reports that Annie McGuire, EVP and General Counsel, disposed of common stock in several transactions. On September 4, 2026, she sold 2,154 shares at a weighted average price of $42.79 and 1,100 shares at a weighted average price of $43.67, in open-market or private transactions made under a Rule 10b5-1 plan adopted on August 29, 2025. On September 2, 2026, 3,215 shares were withheld to satisfy tax obligations upon vesting of restricted stock units, which the company states does not represent a sale.
VERACYTE, INC. (VCYT) reported that Chief Executive Officer and director Marc Stapley had 8,782 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to vesting restricted stock units; this is reported as a disposition but is explicitly described as not representing a sale.
Following this withholding, he directly holds 432,073 shares of Veracyte common stock, which includes 361 shares purchased on July 31, 2026 under the Veracyte, Inc. Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is indicated for this tax-withholding transaction.
VERACYTE, INC. (VCYT) director Muna Bhanji reported selling 1,864 shares of common stock on September 1, 2026 at a price of $42.97 per share in an open-market or private transaction. After this sale, Bhanji directly holds 42,718 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 2, 2026.
VERACYTE, INC. director Karin Eastham reported selling 3,729 shares of common stock on June 18, 2026 in open-market transactions. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 5, 2025, at weighted average prices of $52.78 and $53.55 per share.
EASTHAM KARIN reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Karin Eastham received a grant of 5,272 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost and increase her direct holdings to 18,826 shares following the transaction.
The restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the grant date, or immediately before Veracyte’s next annual stockholder meeting if that occurs earlier. They also vest in full if there is a change in control of the company.
VERACYTE, INC. director Evan Jones received an equity award in the form of 5,272 shares of common stock on June 11, 2026, reported as a grant or other acquisition with no purchase price. Following this award, he directly holds 34,634 shares.
The award represents restricted stock units that vest in full on the first anniversary of the grant date or immediately before the company’s next annual stockholder meeting, whichever occurs first. The units also vest in full if there is a change in control of the issuer.
Shafer David Brent reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director David Brent Shafer received a grant of 5,272 restricted stock units on June 11, 2026 as equity compensation. These units vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier, and also fully vest upon a change in control. Following this award, Shafer directly holds 31,100 shares of Veracyte common stock.
Barr Eliav reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Eliav Barr received a grant of 5,272 shares of common stock in the form of restricted stock units. These RSUs were awarded on June 11, 2026 and increase his direct holdings to 56,461 shares. The units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first. They also vest in full if there is a change in control of the company.
EPSTEIN ROBERT S reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Robert S. Epstein received an equity award in the form of 5,272 shares of common stock on June 11, 2026. The grant was made at a price of $0.00 per share as compensation rather than an open-market purchase. Following this award, Epstein directly holds 57,718 shares of Veracyte common stock. The underlying restricted stock units vest in full on the first anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders, if earlier, and they also vest in full upon a change in control of the issuer.
Holstein Jens reported acquisition or exercise transactions in this Form 4 filing.
Veracyte director Jens Holstein received an equity grant of 5,272 shares of Common Stock on June 11, 2026. The award is in the form of restricted stock units that vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier.
The restricted stock units also vest in full if there is a change in control of Veracyte. After this grant, Holstein directly holds 32,471 shares of Veracyte common stock.
Bhanji Muna reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Muna Bhanji received an equity award in the form of 5,272 shares of common stock on June 11, 2026, granted at no cash cost as a restricted stock unit award. Following the grant, Bhanji directly holds 44,582 shares. The restricted stock units vest in full on the first anniversary of the grant date or immediately before Veracyte’s next annual stockholder meeting, whichever comes first, and they also vest in full if there is a change in control of the company.
Miller Thomas F. reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. director Thomas F. Miller received a grant of 5,272 shares of common stock in the form of restricted stock units on June 11, 2026. These units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first, and also vest in full upon a change in control of the issuer. Following this award, Miller directly holds 31,100 shares of Veracyte common stock.
Veracyte EVP and General Counsel Annie McGuire reported recent share transactions in Veracyte, Inc. common stock. On June 4, 2026, she completed open-market sales of 3,176 shares in total, consisting of 1,776 shares at a weighted average price of $50.1168 per share and 1,400 shares at a weighted average price of $49.3061 per share. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025. Following these sales, she directly held 137,240 shares of Veracyte common stock. On June 2, 2026, 3,292 shares were withheld at $47.80 per share to satisfy tax withholding obligations upon vesting of restricted stock units, which the company notes did not represent a market sale.
VERACYTE, INC. executive Jonathan Wygant, VP and Chief Accounting Officer, reported a tax-related share disposition in company stock. On June 2, 2026, 1,361 shares of common stock were withheld to satisfy his tax withholding obligations tied to the vesting of restricted stock units and did not represent a sale. Following this withholding, he directly holds 44,073 shares of Veracyte common stock.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported recent transactions in the company’s common stock. On June 4, 2026, she executed two open-market sales totaling 3,561 shares at weighted average prices of $49.2836 and $50.0913 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2025.
Separately, on June 2, 2026, 3,693 shares were withheld to cover tax obligations upon the vesting of restricted stock units; this was not an open-market sale. After these transactions, Chambers directly holds 173,280 shares of Veracyte common stock.
VERACYTE, INC. Chief Scientific & Medical Officer Phillip G. Febbo reported a routine share disposition tied to equity compensation. On June 2, 2026, 3,730 shares of common stock were withheld at $47.80 per share to cover tax withholding obligations from vesting restricted stock units, and the company notes this does not represent a market sale. Following this tax withholding event, Febbo directly holds 149,797 shares of common stock.
Veracyte, Inc. chief executive Marc Stapley reported an exercise-and-sale transaction in company stock. On June 4, 2026 he exercised stock options covering 138,051 shares of common stock at $36.60 per share and sold the same 138,051 shares in open-market trades at a weighted average price of $50.1234 per share pursuant to a Rule 10b5-1 plan.
The filing shows 9,012 shares of common stock were withheld on June 2, 2026 to cover tax obligations tied to vesting restricted stock units, which the company notes does not represent a sale. Following these transactions, Stapley directly owns 440,494 shares of Veracyte common stock.
VERACYTE, INC. Global Chief Commercial Officer John Leite reported an open-market sale of 13,975 shares of common stock on June 4, 2026 at a weighted average price of about $50.07 per share, executed under a pre-arranged Rule 10b5-1 plan. On June 2, 2026, 4,059 shares were withheld to satisfy tax obligations from vesting restricted stock units, which was not a market sale. Following these transactions, Leite directly holds 132,305 shares of Veracyte common stock.
VERACYTE, INC. Vice President and Chief Accounting Officer Jonathan Wygant reported an exercise-and-sell transaction in company stock. On May 22, 2026, he exercised stock options for 24,000 shares of common stock at $24.80 per share, then sold 24,000 shares of common stock in an open-market sale at a weighted average price of $45.401 per share, with individual sale prices ranging from $45.07 to $45.69. Following these transactions, he directly owns 45,434 shares of Veracyte common stock. The option exercised is reported as fully vested and, after exercise, no remaining shares from that option grant are outstanding.
VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these sales, Epstein directly owns 52,446 shares of Veracyte common stock.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling a total of 10,204 shares of common stock in open-market transactions on May 6, 2026. The shares were sold in two blocks at $40.00 and $38.05 per share.
After these sales, she directly owns 143,708 shares of Veracyte common stock. According to a footnote, the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025, indicating they were scheduled in advance.
Haas Kevin Richard reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. Chief Dev and Tech Officer Kevin Richard Haas received a grant of 44,221 shares of Common Stock on April 10, 2026 as equity compensation. These are restricted stock units awarded at no cash cost to him.
The RSUs vest 25% on June 2, 2027, with the remaining portion vesting in equal 1/16 increments each quarter thereafter, subject to his continued employment on each vesting date. After this grant, he holds 44,221 shares directly according to the filing.
Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that its VP and Chief Accounting Officer, Jonathan Wygant, received an equity award in the form of 10,525 shares of common stock on March 6, 2026. The shares were granted at no cash cost to him as part of compensation.
According to the award terms, these restricted stock units vest 25% on March 2, 2027, then 1/16 of the grant vests each quarter after that date, subject to his continued employment on each vesting date. Following this award, he directly holds 45,434 shares of Veracyte common stock.
McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that SVP and General Counsel Annie McGuire received two equity grants of common stock on March 6, 2026, both at no cash cost to her. Following these awards, she directly holds 153,912 shares.
The first grant of 32,892 restricted stock units vests 25% on March 2, 2027 and then 1/16 each quarter, subject to her continued employment on each vesting date. The second grant of 26,314 restricted stock units vests in full on the first anniversary of the grant, also contingent on continued employment.
Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in the form of common stock on March 6, 2026. He was granted 29,603 shares and an additional 6,578 shares, both at no cash cost to him.
According to the footnotes, the first award, structured as restricted stock units, vests 25% on March 2, 2027 and then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the grant date, also contingent on his continued employment. Following these grants, he directly owns 153,527 shares of Veracyte common stock.
Leite John reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported an equity compensation grant to Chief Commercial Officer-CLIA John Leite. On March 6, 2026, he received two awards of Common Stock totaling 36,181 and 6,578 shares at $0.00 per share as grants rather than open-market purchases or sales. These awards are structured as restricted stock units that vest over time, including a schedule with 25% vesting on March 2, 2027 and quarterly thereafter, and another grant vesting in full on the first anniversary of the grant date, subject to continued employment. Following these transactions, Leite directly owns 150,339 shares of Veracyte common stock.
Stapley Marc reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that Chief Executive Officer Marc Stapley received a grant of 92,099 shares of common stock on March 6, 2026, in the form of restricted stock units. These RSUs vest 25% on March 2, 2027 and 1/16 each quarter thereafter, subject to his continued employment. Following this award, he directly holds 449,653 shares.
Chambers Rebecca reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported two equity compensation awards in the form of restricted stock units tied to shares of common stock. She was granted 36,181 units and 13,157 units on March 6, 2026, both at no purchase price.
Following these awards, Chambers directly holds 180,534 shares of Veracyte common stock. One award vests 25% on March 2, 2027, with the remainder vesting in equal quarterly installments, while the other vests in full on the first anniversary of the grant, in each case conditioned on continued employment through the vesting dates.
VERACYTE, INC. Chief Financial Officer Rebecca Chambers reported selling a total of 18,341 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025.
The transactions were executed at weighted average prices of $35.5476 and $36.3288 per share, with sale price ranges disclosed in the footnotes. Following these sales, the reporting person directly owned 131,196 shares of Veracyte common stock.
Veracyte, Inc. Chief Executive Officer Marc Stapley sold 45,523 shares of common stock on March 4, 2026 in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. The trades occurred at weighted average prices of $35.5553 and $36.2787 per share. Following these sales, he directly owns 357,554 Veracyte shares.
VERACYTE, INC. Chief Commercial Officer-CLIA John Leite reported an open-market sale of common stock under a pre-arranged Rule 10b5-1 trading plan. On March 4, 2026, he sold 5,260 shares at a weighted average price of $35.1868 per share, with individual sale prices ranging from $35.00 to $35.53. After this transaction, he continued to hold 107,580 shares of Veracyte common stock directly.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling 6,658 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on August 29, 2025.
The reported weighted average sale prices were $35.2936 per share for 4,994 shares and $36.3393 per share for 1,664 shares. After these sales, McGuire directly owned 94,706 shares of Veracyte common stock.
Veracyte, Inc. senior vice president and general counsel Annie McGuire reported a tax-related share disposition tied to restricted stock units. On March 2, 2026, 6,902 shares of common stock at $36.01 per share were withheld to cover tax obligations in connection with RSU vesting and did not represent a sale. After this withholding, she directly owned 101,364 shares of Veracyte common stock.
VERACYTE, INC. executive Jonathan Wygant, the VP and Chief Accounting Officer, reported a tax-related share disposition. On March 2, 2026, 3,006 shares of common stock were withheld at $36.01 per share to cover tax obligations from vesting restricted stock units, and the footnote states this does not represent a sale. Following this withholding, he directly holds 34,909 shares of Veracyte common stock, including 495 shares purchased on January 31, 2026 through the company’s Employee Stock Purchase Plan.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported a Form 4 transaction involving company common stock. On March 2, 2026, 7,234 shares were withheld at a price of $36.01 per share to cover tax obligations tied to vesting restricted stock units and, as the disclosure notes, this does not represent a sale. After this tax-withholding disposition, Chambers directly owns 149,537 shares of Veracyte common stock.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported an automatic share disposition related to tax withholding. On March 2, 2026, 7,517 shares of common stock were withheld at a price of $36.01 per share to cover taxes on vesting restricted stock units, leaving him with 112,840 directly owned shares. The filing specifies this did not represent an open-market sale.
Veracyte, Inc. executive Phillip G. Febbo reported two stock transactions on March 2, 2026. The company withheld 6,035 shares of common stock at $36.01 per share to cover his tax obligations from vesting restricted stock units, which is not a market sale. He also completed an open-market sale of 13,425 shares at a weighted average price of $36.1586 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 117,346 shares of Veracyte common stock.
VERACYTE, INC. Chief Executive Officer Marc Stapley reported a tax-related share disposition. On March 2, 2026, 19,455 shares of common stock were withheld to satisfy tax obligations tied to vesting restricted stock units at a reference price of $36.01 per share. Following this withholding, he directly owns 403,077 shares of Veracyte common stock. The footnote clarifies this was not an open-market sale but a tax-withholding transaction.
Veracyte, Inc. Chief Commercial Officer-CLIA John Leite reported equity-related transactions in company common stock. He acquired 47,149 shares on February 26, 2026 from vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 8,905 shares were disposed at $38.75 per share to cover tax withholding obligations tied to this vesting, which the disclosure states does not represent a sale. Following these transactions, he directly owned 120,357 shares of Veracyte common stock.
Veracyte, Inc. Chief Executive Officer Marc Stapley reported equity compensation activity involving the company’s common stock. He acquired 139,074 shares on February 26, 2026 through the vesting of performance-based restricted stock units after the board certified achievement of required performance goals. Of these units, 70,239 PSUs vested immediately, while 68,835 PSUs are scheduled to vest on December 2, 2026, contingent on his continued service. To cover tax withholding obligations from this vesting, 35,841 shares were withheld at $38.75 per share, which the filing states does not represent an open-market sale. Following these transactions, Stapley directly held 422,532 shares of Veracyte common stock.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported equity compensation activity involving the company’s common stock. On February 26, 2026, she acquired 59,324 shares at no cost upon vesting of performance-based restricted stock units after the board certified achievement of performance goals. On the same date, 12,049 shares were withheld at a price of $38.75 per share to cover tax obligations related to this vesting, which the company notes does not represent a sale. Following these transactions, Chambers directly owned 156,771 shares of Veracyte common stock.
VERACYTE, INC. reported an equity award transaction for Chief Scientific & Med Officer Phillip G. Febbo. On February 26, 2026, he acquired 71,806 shares of common stock at $0.00 per share through the vesting of performance-based restricted stock units. According to the award terms, 47,863 PSUs vested on that date and 23,943 additional PSUs are scheduled to vest on December 2, 2026, subject to continued service. To cover tax withholding from the vesting, 24,486 shares were withheld at $38.75 per share, a disposition that did not involve an open-market sale. Following these transactions, he directly owned 136,806 common shares.
Veracyte, Inc. reported that SVP and General Counsel Annie McGuire acquired 50,999 shares of common stock through the vesting of performance-based restricted stock units on February 26, 2026. According to the filing, 21,071 PSUs vested on that date, with 29,928 additional PSUs scheduled to vest on December 2, 2026, subject to her continued service.
The filing also notes that 10,867 shares were withheld to cover tax obligations related to the PSU vesting, which is characterized as a tax-withholding disposition rather than an open-market sale. After these transactions, McGuire directly owned 108,266 shares of Veracyte common stock, including 374 shares purchased earlier under the company’s employee stock purchase plan.
Veracyte, Inc. reported an insider stock sale by its SVP and General Counsel. On 12/16/2025, the officer sold 10,639 shares of common stock at a weighted average price of $43.1277 per share and an additional 100 shares at $43.68 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on August 29, 2025, which automates trades according to preset instructions. Following these sales, the reporting person beneficially owned 67,760 shares of Veracyte common stock, held directly.
Veracyte, Inc. (VCYT) reported an insider stock sale by its Chief Commercial Officer-CLIA. On 11/25/2025, the officer sold 2,808 shares of common stock at $50 per share in a transaction coded "S" (sale). After this trade, the officer beneficially owned 86,291 shares directly. The filing notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, which is designed to allow insiders to sell shares according to a set schedule.
Veracyte, Inc. (VCYT) reported an insider stock sale by one of its directors. According to the Form 4, the director sold 1,106 shares of Veracyte common stock on 11/25/2025 at a weighted average price of $50.2493 per share, with individual trade prices ranging from $50.005 to $50.66. Following this transaction, the director now beneficially owns 29,362 shares of Veracyte common stock in direct ownership.
The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2024. Such plans allow insiders to sell shares according to a preset schedule or conditions, helping separate trading activity from day-to-day decisions about the company.